Neurogranin-level increases in the CSF in mild cognitive impairment and AD predict conversion from mild cognitive impairment to AD23,24 and correlate with hippocampal atrophy and cognitive decline.8,24,25 Increased neurogranin level also correlates with CSF phosphorylated tau (p-tau) 181 and total tau (t-tau)—but not Aβ42—in sAD10,24,26 and DIAD.27 We found that gantenerumab—but not solanezumab—decreased CSF levels of neurogranin at highest dosage. The gene discussed is MAPT; the disease is Cognitive impairment.